Safety and efficacy of denosumab in osteoporotic patients previously treated with other medications: a systematic review and meta-analysis

Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review

(2017) Paul de Boissieu et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

BEYOND DXA: ADVANCES IN CLINICAL APPLICATIONS OF NEW BONE IMAGING TECHNOLOGY

(2016) Monika Pawlowska et al.   Endocrine Practice

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

(2016) Kosuke Ebina et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

(2016) P. D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Atypical Femoral Fractures: A Teaching Perspective

(2015) Aliya A. Khan et al.   CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION CANADIENNE DES RADIOLOGISTES

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

(2015) Benjamin Z Leder et al.   LANCET

Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis

(2015) Lanling Zhang et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers

(2015) Athanasios D. Anastasilakis et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Natural history, reasons for, and impact of low/non-adherence to medications for osteoporosis in a cohort of community-dwelling older women already established on medication: a 2-year follow-up study

(2015) E. M. Clark et al.   OSTEOPOROSIS INTERNATIONAL

Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study

(2015) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

(2015) S. Papapoulos et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab versus zoledronic acid in patients previously treated with zoledronic acid

(2015) A. D. Anastasilakis et al.   OSTEOPOROSIS INTERNATIONAL

Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)

(2014) Toshitaka Nakamura et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Time Course of Bone Mineral Density Changes With Denosumab Compared With Other Drugs in Postmenopausal Osteoporosis: A Dose-Response–Based Meta-Analysis

(2014) Jaap W. Mandema et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review

(2013) Erik F. Eriksen et al.   BONE

Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

(2013) C. Roux et al.   BONE

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis

(2013) Nelson Watts et al.   Endocrine Practice

Denosumab in osteoporosis

(2013) Dima L Diab et al.   Expert Opinion On Drug Safety

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

(2013) Elizabeth Shane et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

(2013) Joy N Tsai et al.   LANCET

Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013

(2013) J. Compston et al.   MATURITAS

Atypical Femoral fractures: A Review of the Literature

(2013) Pingal A. Desai et al.   Current Osteoporosis Reports

High-Resolution Peripheral Quantitative Computed Tomography for the Assessment of Bone Strength and Structure: A Review by the Canadian Bone Strength Working Group

(2013) Angela M. Cheung et al.   Current Osteoporosis Reports

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

(2012) M. R. McClung et al.   OSTEOPOROSIS INTERNATIONAL

Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

(2011) Socrates Papapoulos et al.   JOURNAL OF BONE AND MINERAL RESEARCH

GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates

(2011) P. Hadji et al.   OSTEOPOROSIS INTERNATIONAL

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women

(2011) N. Freemantle et al.   OSTEOPOROSIS INTERNATIONAL

Six-Year Safety and Efficacy Data from Denosumab Phase 2 Extension Study

(2010) Paul D. Miller et al.   JOURNAL OF CLINICAL DENSITOMETRY

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

(2010) D. L. Kendler et al.   OSTEOPOROSIS INTERNATIONAL

Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands

(2010) J. C. Netelenbos et al.   OSTEOPOROSIS INTERNATIONAL

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

(2009) David L Kendler et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE

Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*

(2008) Jacques P Brown et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

(2008) Henry G. Bone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM